基于消化内镜动态大数据的人工智能病变识别系统研究

注册号:

Registration number:

ChiCTR2200063891 

最近更新日期:

Date of Last Refreshed on:

2023-04-24 16:11:25 

注册时间:

Date of Registration:

2022-09-20 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于消化内镜动态大数据的人工智能病变识别系统研究

Public title:

Research on Artificial Intelligence Disease Identification System Based on Dynamic Big Data of Digestive Endoscope

注册题目简写:

多中心消化内镜AI

English Acronym:

Multicenter digestive endoscope AI

研究课题的正式科学名称:

基于消化内镜动态大数据的人工智能病变识别系统研究

Scientific title:

Research on Artificial Intelligence Disease Identification System Based on Dynamic Big Data of Digestive Endoscope

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李帅 

研究负责人:

朱圣韬 

Applicant:

Shuai Li 

Study leader:

Zhu Shengtao 

申请注册联系人电话:

Applicant telephone:

+86 13114599779

研究负责人电话:

Study leader's
telephone:

+86 13111313236

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lsmisty@sina.com

研究负责人电子邮件:

Study leader's E-mail:

zhushengtao@ccmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市西城区永安路95号

研究负责人通讯地址:

北京市西城区永安路95号

Applicant address:

95 Yongan Road, Xicheng District, Beijing

Study leader's address:

95 Yongan Road, Xicheng District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学附属北京友谊医院

Applicant's institution:

Beijing Friendship Hospital,Capital Medical University

研究负责人所在单位:

首都医科大学附属北京友谊医院

Affiliation of the Leader:

Beijing Friendship Hospital,Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022-P2-158-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学附属北京友谊医院生命伦理委员会

Name of the ethic committee:

Bioethics Committee of Beijing Friendship Hospital affiliated to Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2022-05-31 00:00:00

伦理委员会联系人:

李悦

Contact Name of the ethic committee:

Yue Li

伦理委员会联系地址:

北京市西城区永安路95号

Contact Address of the ethic committee:

95 Yongan Road, Xicheng District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

首都医科大学附属北京友谊医院

Primary sponsor:

Beijing Friendship Hospital,Capital Medical University

研究实施负责(组长)单位地址:

北京市西城区永安路95号

Primary sponsor's address:

95 Yongan Road, Xicheng District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京友谊医院

具体地址:

北京市西城区永安路95号

Institution
hospital:

Beijing Friendship Hospital, Capital Medical University

Address:

95 Yongan Road, Xicheng District, Beijing

经费或物资来源:

北京市科学技术委员会

Source(s) of funding:

Beijing Municipal Science and Technology Commission

研究疾病:

萎缩性胃炎,结肠息肉,结肠腺瘤  

Target disease:

Atrophic gastritis, polyp, adenoma

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

诊断试验新技术临床试验 

Study phase:

Diagnostic New Technique Clincal Study

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

对消化内镜动态大数据的人工智能病变识别系统(AI系统)临床使用的安全性和有效性进行评价。  

Objectives of Study:

To evaluate the safety and effectiveness of clinical application of artificial intelligence lesion identification system (AI system) for digesting endoscopic dynamic big data.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.既往有急性心梗病史,有严重的心、肝肾功能不全,或精神疾患。
2.正在服用阿司匹林、华法林等抗凝药者。
3.炎症性肠病复查及结息肉病者 ;
4.胃或结肠切除病史的受试者;
5.有家族性息肉病的患者;
6.研究者认为不适合参加本临床试验的受试者。

Exclusion criteria:

1. Previous history of acute myocardial infarction, severe heart, liver, and kidney dysfunction, or mental illness.
2. Those who are taking anticoagulants such as aspirin and warfarin.
3. Patients with inflammatory bowel disease and colon polyp disease;
4. Subjects with a history of gastric or colon resection;
5. Patients with familial polyposis;
6. Subjects deemed unsuitable by the researchers to participate in this clinical trial.

研究实施时间:

Study execute time:

From 2022-09-20 00:00:00 To 2022-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-09-20 00:00:00 To 2022-12-31 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

968

Group:

control group

Sample size:

干预措施:

不进行干预

干预措施代码:

Intervention:

Nothing

Intervention code:

组别:

实验组

样本量:

968

Group:

Experimental group

Sample size:

干预措施:

应用AI产品

干预措施代码:

Intervention:

Applied AI products

Intervention code:

组别:

软件独立判断结果组

样本量:

1936

Group:

Software independent judgment result group

Sample size:

干预措施:

进行软件独立诊断

干预措施代码:

Intervention:

Perform software independent diagnosis

Intervention code:

组别:

专家诊断结果组

样本量:

1936

Group:

Expert diagnosis result group

Sample size:

干预措施:

第三方专家独立评价

干预措施代码:

Intervention:

Independent evaluation by third-party experts

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京友谊医院 

单位级别:

三甲 

Institution
hospital:

Beijing Friendship Hospital,Capital Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京市平谷区医院 

单位级别:

三甲 

Institution
hospital:

Beijing Pinggu District Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京王府中西医结合医院 

单位级别:

三甲 

Institution
hospital:

Beijing royal integrative medicine hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东 

市(区县):

济南 

Country:

China

Province:

Shandong

City:

Ji'nan

单位(医院):

山东省立医院 

单位级别:

三甲 

Institution
hospital:

Shandong provincial hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东 

市(区县):

日照 

Country:

China

Province:

Shandong

City:

Rizhao

单位(医院):

日照市人民医院 

单位级别:

三甲 

Institution
hospital:

Rizhao people's hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东 

市(区县):

潍坊 

Country:

China

Province:

Shandong

City:

Weifang

单位(医院):

潍坊医学院附属医院 

单位级别:

三甲 

Institution
hospital:

Weifang Medical College Affiliated Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东 

市(区县):

聊城 

Country:

China

Province:

Shandong

City:

Liaocheng

单位(医院):

聊城市第二人民医院 

单位级别:

三甲 

Institution
hospital:

Liaocheng No.2 People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

内蒙古 

市(区县):

包头 

Country:

China

Province:

Nei Mongol

City:

Baotou

单位(医院):

包头市中心医院 

单位级别:

三甲 

Institution
hospital:

Baotou central hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西 

市(区县):

西安 

Country:

China

Province:

Shaanxi

City:

Xi'an

单位(医院):

西电集团医院 

单位级别:

三甲 

Institution
hospital:

Xd group Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川 

市(区县):

攀枝花 

Country:

China

Province:

Sichuan

City:

PanZhihua

单位(医院):

攀钢集团总医院 

单位级别:

三甲 

Institution
hospital:

Pangang group general hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

辽宁 

市(区县):

鞍山 

Country:

China

Province:

Liaoning

City:

Anshan

单位(医院):

鞍钢集团总医院 

单位级别:

三甲 

Institution
hospital:

Angang group general hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

结肠息肉识别敏感性、特异性

指标类型:

主要指标

Outcome:

Sensitivity and specificity of polyps detection

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

萎缩性胃炎及结肠息肉、腺瘤的检出率

指标类型:

主要指标

Outcome:

Detection rate of atrophic gastritis, polyps and adenomas

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

软件独立识别组结肠息肉病变识别的敏感性和特异性

指标类型:

次要指标

Outcome:

Sensitivity and specificity of identification of polyps in software

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

软件独立识别组萎缩性胃炎及结肠腺瘤的检出率

指标类型:

次要指标

Outcome:

Detection rate of atrophic gastritis and adenoma in software group

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良事件发生率

指标类型:

副作用指标

Outcome:

Incidence rate of adverse events

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

严重不良事件发生率

指标类型:

副作用指标

Outcome:

Incidence of serious adverse events

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

分层区组随机

Randomization Procedure (please state who generates the random number sequence and by what method):

Stratified block randomization

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

NO

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用病例记录表收集数据,SPSS进行数据管理。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Report Form for data collection. SPSS for data management.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2022-09-20 11:40:35